Development, upscaling and validation of the purification process for human-cl rhFVIII (Nuwiq®), a new generation recombinant factor VIII produced in a human cell-line

Protein Expression and Purification

Volumn 115, Issue , 2015, Pages 165-175

  Winge, Stefan ^a   Yderland, Louise ^a   Kannicht, Christoph ^b   Hermans, Pim ^c   Adema, Simon ^c   Schmidt, Torben ^d   Gilljam, Gustav ^a   Linhult, Martin ^a   Tiemeyer, Maya ^e   Belyanskaya, Larisa ^f   Walter, Olaf ^f  

^a Octapharma AB   (Sweden)

^b Octapharma Molecular Biochemistry   (Germany)

^c Thermo Fisher Scientific   (United States)

^d Octapharma   (Germany)

^e Octapharma Biopharmaceuticals GmbH   (Germany)

^f Octapharma AG Lachen   (Switzerland)

Author keywords

Haemophilia A; Human cl rhFVIII; Nuwiq ; Pathogen safety; Purification process; Recombinant factor VIII

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT PROTEIN;

CHEMISTRY; HEK293 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; LIQUID CHROMATOGRAPHY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROCEDURES; REPRODUCIBILITY; STANDARDS;

CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR VIII; HEK293 CELLS; HUMANS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 84941939221     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2015.08.023     Document Type: Article

References (44)

1. A. Coppola, M. Di Capua, M.N. Di Minno, M. Di Palo, E. Marrone, P. Ierano, C. Arturo, A. Tufano, and A.M. Cerbone Treatment of hemophilia: a review of current advances and ongoing issues J. Blood Med. 1 2010 183 195
2. M. Franchini The modern treatment of haemophilia: a narrative review Blood Transfus. 11 2013 178 182
3. K. Fischer, J.G. Bom, E.P. Mauser-Bunschoten, G. Roosendaal, and H.M. Berg Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters Haemophilia 11 2005 43 48
4. T.M. Brown, W.C. Lee, A.V. Joshi, and C.L. Pashos Health-related quality of life and productivity impact in haemophilia patients with inhibitors Haemophilia 15 2009 911 917
5. S.C. Darby, D.M. Keeling, R.J. Spooner, S. Wan Kan, P.L. Giangrande, P.W. Collins, F.G. Hill, C.R. Hay U.K.H.C.D. Organisation The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 J. Thromb. Haemost. 2 2004 1047 1054
6. M. Morfini, S. Haya, G. Tagariello, H. Pollmann, M. Quintana, B. Siegmund, N. Stieltjes, G. Dolan, and J. Tusell European study on orthopaedic status of haemophilia patients with inhibitors Haemophilia 13 2007 606 612
7. A. Gringeri, L.G. Mantovani, L. Scalone, P.M. Mannucci C.S. Group Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group Blood 102 2003 2358 2363
8. J. Astermark Prevention and prediction of inhibitor risk Haemophilia 18 Suppl. 4 2012 38 42
9. S.C. Gouw, J.G. van der Bom, R. Ljung, C. Escuriola, A.R. Cid, S. Claeyssens-Donadel, C. van Geet, G. Kenet, A. Makipernaa, A.C. Molinari, W. Muntean, R. Kobelt, G. Rivard, E. Santagostino, A. Thomas, H.M. van den Berg PedNet, R.S. Group Factor VIII products and inhibitor development in severe hemophilia A N. Engl. J. Med. 368 2013 231 239
10. M. Xi, M. Makris, M. Marcucci, E. Santagostino, P.M. Mannucci, and A. Iorio Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression J. Thromb. Haemost. 11 2013 1655 1662
11. P.J. Lenting, O.D. Christophe, and P. Gueguen The disappearing act of factor VIII Haemophilia 16 2010 6 15
12. M.P. Kosloski, R.D. Miclea, and S.V. Balu-Iyer Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII AAPS J. 11 2009 424 431
13. A. Leyte, H.B. Van Schijndel, C. Niehrs, W.B. Huttner, M.P. Verbeet, K. Mertens, and J.A. van Mourik Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor J. Biol. Chem. 266 1991 740 746
14. S.A. Brooks Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system Mol. Biotechnol. 28 2004 241 255
15. C. Kannicht, M. Ramstrom, G. Kohla, M. Tiemeyer, E. Casademunt, O. Walter, and H. Sandberg Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII Thromb. Res. 131 2013 78 88
16. P.L. Chiu, G.M. Bou-Assaf, E. Seth Chhabra, M.G. Chambers, R.T. Peters, J.D. Kulman, and T. Walz Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry Blood 2015
17. E. Casademunt, K. Martinelle, M. Jernberg, S. Winge, M. Tiemeyer, L. Biesert, S. Knaub, O. Walter, and C. Schroder The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics Eur. J. Haematol. 89 2012 165 176
18. H. Sandberg, C. Kannicht, P. Stenlund, M. Dadaian, U. Oswaldsson, C. Cordula, and O. Walter Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII Thromb. Res. 130 2012 808 817
19. L.A. Valentino, C. Negrier, G. Kohla, A. Tiede, R. Liesner, D. Hart, and S. Knaub The first recombinant FVIII produced in human cells - an update on its clinical development programme Haemophilia 20 Suppl. 1 2014 1 9
20. J. McCue, D. Osborne, J. Dumont, R. Peters, B. Mei, G.F. Pierce, K. Kobayashi, and D. Euwart Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein Haemophilia 20 2014 e327 e335
21. B. Kelley, M. Jankowski, and J. Booth An improved manufacturing process for Xyntha/ReFacto AF Haemophilia 16 2010 717 725
22. B.G. Boedeker Production processes of licensed recombinant factor VIII preparations Semin. Thromb. Hemost. 27 2001 385 394
23. R. Jiang, T. Monroe, R. McRogers, and P.J. Larson Manufacturing challenges in the commercial production of recombinant coagulation factor VIII Haemophilia 8 Suppl. 2 2002 1 5
24. M. Griffith, H. Kingdon, S.L. Liu, and W. Burkart In-process controls and characterization of recombinate antihemophilic factor (recombinant) Ann. Hematol. 63 1991 166 171
25. L. Thim, B. Vandahl, J. Karlsson, N.K. Klausen, J. Pedersen, T.N. Krogh, M. Kjalke, J.M. Petersen, L.B. Johnsen, G. Bolt, P.L. Norby, and T.D. Steenstrup Purification and characterization of a new recombinant factor VIII (N8) Haemophilia 16 2010 349 359
26. S. Winge, Method for improved isolation of recombinantly produced proteins. Patent application PCT/WO 2006103258-A1, published 2006.
27. G. Gilljam, M. Jernberg, S. Winge, A. Neisser-Svae, A process for isolation and purification of a target protein free of prion protein (prpsc). Patent application PCT/WO 2009024620-A2, published 2009.
28. C. Borgvall, U. Ericsson, G. Gilljam, M. Jernberg, S. Winge, A process of purifying coagulation factor VIII. Patent application PCT/WO 2009156430-A1, published 2009.
29. S. Winge, E. Johansson, M. Dadaian, B. Fuchs, A process for manufacturing Factor VIII having an improved ratio of FVIII:C/FVIII:Ag. PCT/EP2015/051028, filed 2015.
30. C. Hauser, A. Hoerster, C. Schroeder, M. Lehnerer, Production of recombinant blood clotting factors in human cell lines. Patent application PCT/WO 2001070968-A2, published 2001.
31. C. Schroeder, C. Wegmann, H. Ding, Serum-free stable transfection and production of recombinant human proteins in human cell lines. Patent application PCT/WO 2010020690-A1, published 2010.
32. I. Agerkvist, P. Aizawa, A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII. Patent application PCT/WO 2012156356-A1, published 2012.
33. S. Rosen Assay of factor VIII: C with a chromogenic substrate Scand. J. Haematol. Suppl. 40 1984 139 145
34. G. Carlebjork, U. Oswaldsson, and S. Rosen A simple and accurate microplate assay for the determination of factor VIII activity Thromb. Res. 47 1987 5 14
35. A.R. Mire-Sluis, T. Gerrard, R.G. Das, A. Padilla, and R. Thorpe Biological assays: their role in the development and quality control of recombinant biological medicinal products Biologicals 24 1996 351 362
36. J.P. Girma, E. Fressinaud, A. Houllier, Y. Laurian, J. Amiral, and D. Meyer Assay of factor VIII antigen (VIII:CAg) in 294 haemophilia A patients by a new commercial ELISA using monoclonal antibodies Haemophilia 4 1998 98 103
37. N. Umetani, J. Kim, S. Hiramatsu, H.A. Reber, O.J. Hines, A.J. Bilchik, and D.S. Hoon Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats Clin. Chem. 52 2006 1062 1069
38. M.M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding Anal. Biochem. 72 1976 248 254
39. E. Engvall, and P. Perlmann Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G Immunochemistry 8 1971 871 874
40. D. Ejima, K. Tsumoto, and T. Arakawa Biotech applications of arginine BioProcess Int. 3 2005 20 28
41. P.L. Roberts Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII Biologicals 36 2008 330 335
42. B. Rippner, J. Österberg, U. Nilsson, E. Ivarsson, I. Agerkvist, New protecting compositions for recombinantly produced factor VIII. Patent application PCT/WO 2010026186-A1, published 2010.
43. H. Sandberg, P. Stenlund, C. Schröder, E. Casademunt, M. Tiemeyer, Recombinantly produced human factor VIII and IX. Patent application PCT/WO 2010020690-A1, published 2010.
44. J.C. Lin, R.A. Ettinger, J.T. Schuman, A.H. Zhang, M. Wamiq-Adhami, P.C. Nguyen, S.M. Nakaya-Fletcher, K. Puranik, A.R. Thompson, and K.P. Pratt Six amino acid residues in a 1200 A2 interface mediate binding of factor VIII to an IgG4kappa inhibitory antibody PLoS ONE 10 2015 e0116577